Dopamine transporter-mediated cytotoxicity of 6-hydroxydopamine in vitro depends on expression of mutant α-synucleins related to Parkinson's disease

Abad, 1995, Pharmacological protection against the cytotoxicity induced by 6-hydroxydopamine and H2O2 in chromaffin cells, Eur. J. Pharmacol., 293, 55, 10.1016/0926-6917(95)90018-7 Ancolio, 2000, Alpha-synuclein and the Parkinson's disease-related mutant Ala53Thr-alpha-synuclein do not undergo proteasomal degradation in HEK293 and neuronal cells, Neurosci. Lett., 285, 79, 10.1016/S0304-3940(00)01049-1 Andrew, 1993, The determination of hydroxydopamines and other trace amines in the urine of Parkinsonian patients and normal controls, Neurochem. Res., 18, 1175, 10.1007/BF00978370 Breese, 1970, Effect of 6-hydroxydopamine on brain norepinephrine and dopamine evidence for selective degeneration of catecholamine neurons, J Pharmacol. Exp. Ther., 174, 413 Brown, 1992, Control of respiration and ATP synthesis in mammalian mitochondria and cells, Biochem. J., 284, 1, 10.1042/bj2840001 Buck, 1994, Chimeric dopamine-norepinephrine transporters delineate structural domains influencing selectivity for catecholamines and 1-methyl-4-phenylpyridinium, Proc. Natl. Acad. Sci. U.S.A., 91, 12584, 10.1073/pnas.91.26.12584 Cadet, 1989, Vitamin E attenuates the toxic effects of intrastriatal injection of 6-hydroxydopamine (6-OHDA) in rats: behavioral and biochemical evidence, Brain Res., 476, 10, 10.1016/0006-8993(89)91530-8 Cerruti, 1993, Protection by BTCP of cultured dopaminergic neurons exposed to neurotoxins, Brain Res., 617, 138, 10.1016/0006-8993(93)90624-V Chartier-Harlin, 2004, Alpha-synuclein locus duplication as a cause of familial Parkinson's disease, Lancet, 364, 1167, 10.1016/S0140-6736(04)17103-1 Conway, 2001, Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct, Science, 294, 1346, 10.1126/science.1063522 Da Costa, 1999, Comparative analysis of three methods to assess viability of mammalian cells in culture, Biocell, 23, 65 Dauer, 2002, Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP, Proc. Natl. Acad. Sci. U.S.A., 99, 14524, 10.1073/pnas.172514599 Decker, 1993, Competitive irreversible inhibition of dopamine uptake by 6-hydroxydopamine, Res. Commun. Chem. Pathol. Pharmacol., 79, 195 Glinka, 1996, Nature of inhibition of mitochondrial respiratory complex I by 6-hydroxydopamine, J. Neurochem., 66, 2004, 10.1046/j.1471-4159.1996.66052004.x Glinka, 1997, Mechanism of 6-hydroxydopamine neurotoxicity, J. Neural Transm. Suppl., 50, 55, 10.1007/978-3-7091-6842-4_7 Glinka, 1998, Mechanism of inhibition of mitochondrial respiratory complex I by 6-hydroxydopamine and its prevention by desferrioxamine, Eur. J. Pharmacol., 351, 121, 10.1016/S0014-2999(98)00279-9 Glinka, 1995, Inhibition of mitochondrial complexes I and IV by 6-hydroxydopamine, Eur. J. Pharmacol., 292, 329, 10.1016/0926-6917(95)90040-3 Hermann, 2004, Efficient generation of neural stem cell-like cells from adult human bone marrow stromal cells, J. Cell Sci., 117, 4411, 10.1242/jcs.01307 Hirsch, 2003, Animal models of Parkinson's disease in rodents induced by toxins: an update, J. Neural Transm. Suppl., 89, 10.1007/978-3-7091-0643-3_6 Jellinger, 1995, Chemical evidence for 6-hydroxydopamine to be an endogenous toxic factor in the pathogenesis of Parkinson's disease, J. Neural Transm. Suppl., 46, 297 Jonsson, 1971, Uptake and accumulation of 3H-6-hydroxydopamine in adrenergic nerves, Eur. J. Pharmacol., 16, 55, 10.1016/0014-2999(71)90056-2 Kienzl, 1995, The role of transition metals in the pathogenesis of Parkinson's disease, J. Neurol. Sci., 134, 69, 10.1016/0022-510X(95)00210-S Kitayama, 1998, MPP+ toxicity and plasma membrane dopamine transporter: study using cell lines expressing the wild-type and mutant rat dopamine transporters, Biochim. Biophys. Acta, 1404, 305, 10.1016/S0167-4889(98)00071-8 Kostrzewa, 1974, Pharmacological actions of 6-hydroxydopamine, Pharmacol. Rev., 26, 199 Kruger, 2000, Involvement of alpha-synuclein in Parkinson's disease and other neurodegenerative disorders, J. Neural. Transm., 107, 31, 10.1007/s007020050002 Kruger, 1998, Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease, Nat. Genet., 18, 106, 10.1038/ng0298-106 Kumar, 1995, Free radical-generated neurotoxicity of 6-hydroxydopamine, J. Neurochem., 64, 1703, 10.1046/j.1471-4159.1995.64041703.x Kurosaki, 2002, Role of nitric oxide synthase against MPTP neurotoxicity in mice, Neurol. Res., 24, 655, 10.1179/016164102101200717 Lashuel, 2002, Neurodegenerative disease: amyloid pores from pathogenic mutations, Nature, 418, 291, 10.1038/418291a Lee, 2005, Inhibition of MPP+-induced mitochondrial damage and cell death by trifluoperazine and W-7 in PC12 cells, Neurochem. Int., 46, 169, 10.1016/j.neuint.2004.07.007 Lee, 2001, Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis, Faseb J., 15, 916, 10.1096/fj.00-0334com Lee, 2001, Effect of the overexpression of wild-type or mutant alpha-synuclein on cell susceptibility to insult, J. Neurochem., 76, 998, 10.1046/j.1471-4159.2001.00149.x Lehmensiek, 2002, Expression of mutant alpha-synucleins enhances dopamine transporter-mediated MPP+ toxicity in vitro, Neuroreport, 13, 1279, 10.1097/00001756-200207190-00013 Lin, 2004, Differential effects of carboxyfullerene on MPP+/MPTP-induced neurotoxicity, Neurochem. Int., 44, 99, 10.1016/S0197-0186(03)00113-X Linert, 1996, Dopamine, 6-hydroxydopamine, iron, and dioxygen — their mutual interactions and possible implication in the development of Parkinson's disease, Biochim. Biophys. Acta, 1316, 160, 10.1016/0925-4439(96)00020-8 Ljungdahl, 1971, Autoradiographic demonstration of uptake and accumulation of 3H-6-hydroxydopamine in adrenergic nerves, Experientia, 27, 297, 10.1007/BF02138157 Matsubara, 1998, Structural significance of azaheterocyclic amines related to Parkinson's disease for dopamine transporter, Eur. J. Pharmacol., 348, 77, 10.1016/S0014-2999(98)00131-9 Menzies, 2002, Mitochondrial dysfunction in a cell culture model of familial amyotrophic lateral sclerosis, Brain, 125, 1522, 10.1093/brain/awf167 Mezey, 1998, Alpha synuclein in neurodegenerative disorders: murderer or accomplice?, Nat. Med., 4, 755, 10.1038/nm0798-755 Michel, 1990, Toxicity of 6-hydroxydopamine and dopamine for dopaminergic neurons in culture, J. Neurosci. Res., 26, 428, 10.1002/jnr.490260405 Muramatsu, 2002, Therapeutic effect of neuronal nitric oxide synthase inhibitor (7-nitroindazole) against MPTP neurotoxicity in mice, Metab. Brain. Dis., 17, 169, 10.1023/A:1020025805287 Perumal, 1992, Vitamin E attenuates the toxic effects of 6-hydroxydopamine on free radical scavenging systems in rat brain, Brain Res. Bull., 29, 699, 10.1016/0361-9230(92)90142-K Pifl, 1993, Dopamine transporter expression confers cytotoxicity to low doses of the Parkinsonism-inducing neurotoxin 1-methyl-4-phenylpyridinium, J. Neurosci., 13, 4246, 10.1523/JNEUROSCI.13-10-04246.1993 Pifl, 1996, Catecholamine transporters and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity: studies comparing the cloned human noradrenaline and human dopamine transporter, J. Pharmacol. Exp. Ther., 277, 1437 Polymeropoulos, 1997, Mutation in the alpha-synuclein gene identified in families with Parkinson's disease, Science, 276, 2045, 10.1126/science.276.5321.2045 Przedborski, 1998, Mechanisms of MPTP toxicity, Movement Disord., 13, 35 Rosenberg, 1988, Catecholamine toxicity in cerebral cortex in dissociated cell culture, J. Neurosci., 8, 2887, 10.1523/JNEUROSCI.08-08-02887.1988 Sidhu, 2004, alpha-Synuclein regulation of the dopaminergic transporter: a possible role in the pathogenesis of Parkinson's disease, FEBS Lett., 565, 1, 10.1016/j.febslet.2004.03.063 Singleton, 2003, Alpha-synuclein locus triplication causes Parkinson's disease, Science, 302, 841, 10.1126/science.1090278 Spillantini, 1997, Alpha-synuclein in Lewy bodies, Nature, 388, 839, 10.1038/42166 Stocchi, 1985, Simultaneous extraction and reverse-phase high-performance liquid chromatographic determination of adenine and pyridine nucleotides in human red blood cells, Anal. Biochem., 146, 118, 10.1016/0003-2697(85)90405-1 Storch, 1999, HEK-293 cells expressing the human dopamine transporter are susceptible to low concentrations of 1-methyl-4-phenylpyridine (MPP+) via impairment of energy metabolism, Neurochem. Int., 35, 393, 10.1016/S0197-0186(99)00083-2 Storch, 2004, Dopamine transporter: involvement in selective dopaminergic neurotoxicity and degeneration, J. Neural Transm., 111, 1267, 10.1007/s00702-004-0203-2 Storch, 2000, 6-Hydroxydopamine toxicity towards human SH-SY5Y dopaminergic neuroblastoma cells: independent of mitochondrial energy metabolism, J. Neural Transm., 107, 281, 10.1007/s007020050023 Storch, 2000, 1-Methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline (salsolinol) is toxic to dopaminergic neuroblastoma SH-SY5Y cells via impairment of cellular energy metabolism, Brain Res., 855, 67, 10.1016/S0006-8993(99)02272-6 Storch, 2004, Dopamine transporter-mediated cytotoxicity of beta-carbolinium derivatives related to Parkinson's disease: relationship to transporter-dependent uptake, J. Neurochem., 89, 685, 10.1111/j.1471-4159.2004.02397.x Storch, 2002, Selective dopaminergic neurotoxicity of isoquinoline derivatives related to Parkinson's disease: studies using heterologous expression systems of the dopamine transporter, Biochem. Pharmacol., 63, 909, 10.1016/S0006-2952(01)00922-4 Tabrizi, 2000, Expression of mutant alpha-synuclein causes increased susceptibility to dopamine toxicity, Hum. Mol. Genet., 9, 2683, 10.1093/hmg/9.18.2683 Vila, 2004, Genetic clues to the pathogenesis of Parkinson's disease, Nat. Med., 10, S58, 10.1038/nm1068 Volles, 2002, Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism, Biochemistry, 41, 4595, 10.1021/bi0121353 Volles, 2003, Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease, Biochemistry, 42, 7871, 10.1021/bi030086j Watanabe, 2004, Protective effects of neuronal nitric oxide synthase inhibitor in mouse brain against MPTP neurotoxicity: an immunohistological study, Eur. Neuropsychopharmacol., 14, 93, 10.1016/S0924-977X(03)00065-8 Wersinger, 2003, Attenuation of dopamine transporter activity by alpha-synuclein, Neurosci. Lett., 340, 189, 10.1016/S0304-3940(03)00097-1 Wersinger, 2004, Trypsin disrupts the trafficking of the human dopamine transporter by alpha-synuclein and its A30P mutant, Biochemistry, 43, 1242, 10.1021/bi035308s Wersinger, 2004, Comparative analyses of alpha-synuclein expression levels in rat brain tissues and transfected cells, Neurosci. Lett., 358, 95, 10.1016/j.neulet.2003.12.118 Wersinger, 2003, Modulation of dopamine transporter function by alpha-synuclein is altered by impairment of cell adhesion and by induction of oxidative stress, Faseb J., 17, 2151, 10.1096/fj.03-0152fje Wersinger, 2003, Mutations in the lipid-binding domain of alpha-synuclein confer overlapping, yet distinct, functional properties in the regulation of dopamine transporter activity, Mol. Cell. Neurosci., 24, 91, 10.1016/S1044-7431(03)00124-6 Woodgate, 1999, The toxicity of 6-hydroxydopamine on PC12 and P19 cells., Brain Res. Mol. Brain Res., 69, 84, 10.1016/S0169-328X(99)00103-5 Zhou, 2000, Overexpression of human alpha-synuclein causes dopamine neuron death in rat primary culture and immortalized mesencephalon-derived cells, Brain Res., 866, 33, 10.1016/S0006-8993(00)02215-0